Greater likelihood of low disease activity and remission were associated with being male, younger age, lower health assessment questionnaire, ESR (or CRP) and TJC (or SJC) scores and absence of comorbidities in golimumab-treated RA patients (179). This evidence concerns the gene CRP and rheumatoid arthritis.